Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683422 · ClinicalTrials.gov registry record · NA
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
A NA study, sponsored by Loma Linda University.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT01683422 is a NA study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 9 participants.
The verdict
NCT01683422, a NA study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
The current trial will provide important data on the recurrence rates and patterns of failure using state of the art target agent, chemotherapy and proton beam technology for patients with Locally Advanced Pancreatic Cancer (LAPC). A median survival of 10 months or greater would be considered evidence of a regimen potentially worthy of further study as a new treatment paradigm in one arm in a future phase III trial.
Interventions
- RADIATION Proton Radiation
- RADIATION Proton, Gemcitabine, Erlotinib, Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-01-02 |
| Est. Completion | 2019-02-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01683422
The ClinicalTrials.gov registry entry for NCT01683422 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Proton Radiation is the first listed.
NCT01683422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01683422 about?
NCT01683422 is a clinical study titled "Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer". The current trial will provide important data on the recurrence rates and patterns of failure using state of the art target agent, chemotherapy and proton beam technology for patients with Locally Advanced Pancreatic Cancer (LAPC). A median survival of 10 months or greater would be considered eviden...
What is the current status of trial NCT01683422?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2013-01-02. Estimated completion is 2019-02-19.
What interventions are being tested in trial NCT01683422?
The interventions under investigation include: Proton Radiation (RADIATION), Proton, Gemcitabine, Erlotinib, Capecitabine (RADIATION).
Who is sponsoring clinical trial NCT01683422?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.